Document › Details
Bruker Corporation. (9/27/10). "Press Release: BEST Subsidiary RI Research Awarded Contract for High-power RF Couplers for European XFEL in Consortium with Thales". Bergisch Gladbach.
|Organisation||RI Research Instruments GmbH|
|Group||Bruker Corporation (Group)|
|Product 2||superconductor tape|
|Person||Peiniger, Michael (Bruker 200904 Managing Director + minority owner RI Research Instruments GmbH)|
|Person 2||Vogel, Hanspeter (Bruker 201009 Director RI Research Instruments GmbH)|
RI Research Instruments GmbH (RI), a majority-owned subsidiary of Bruker Energy & Supercon Technologies, Inc. (BEST), today announced a new contract from the Centre National de la Recherche Scientifique (CNRS) in France for the supply of 670 high-power radio frequency (rf) couplers for the European XFEL project. This 14.8 million Euro (approximately $20 million USD) contract has been awarded to a project consortium of Thales Electron Devices (TED), located in Velizy, France, and RI Research Instruments, under the leadership of TED. Each company contributes its specialized technological expertise, and RI's financial share of the total contract is just under 50%. These rf couplers are expected to be delivered between the beginning of 2011 and the middle of 2013.
The European XFEL is designed with a 17.5 GeV linear accelerator which will use superconducting rf cavities and associated high-power rf couplers to deliver electron bunches for the generation of X-ray flashes in special magnetic undulators. High-power rf couplers represent a key component of superconducting accelerating modules, and transfer the rf from the power source to the accelerating cavity. Several key, specialized RI technologies and process capabilities, such as the coating of metal or ceramic surfaces, vacuum brazing, tungsteninert gas(TIG) and electron beam welding, as well as clean room assembly, are applied to manufacture such rf couplers.
Dr. Michael Peiniger, Managing Director of RI Research Instruments, explained: "With Thales we have found a partner with excellent technical and management skills. Thales complements the RI know-how in this field, as demonstrated in more than 60 high-power rf couplers of similar design that RI has successfully delivered to CNRS and DESY in the past. Thales is a world leader in rf power sources, and RI is a leader in superconducting rf accelerator technology."
Note: This rf coupler contract from CNRS is separate from, and in addition to, RI's 24.9 million Euro XFEL superconducting rf cavities contract from DESY, announced on September 22, 2010.
About RI Research Instruments and Bruker Energy & Supercon Technologies, Inc.:
RI Research Instruments GmbH is a world leader in the development and manufacturing of normal and superconducting rf cavities and systems, linear accelerators, as well as special products for physics and energy research, scientific, medical and industrial applications. RI products also include high-performance electron and ion sources, particle beamlines and diagnostics, research reactor subunits as well as vacuum and cryogenic systems. BEST has operations in the US, the UK and Germany, and is a wholly-owned subsidiary of Bruker Corporation (NASDAQ: BRKR).
For more information, please visit: www.research-instruments.de or www.bruker-est.com.
CAUTIONARY STATEMENT OF BEST
This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In many cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "continue" or other similar words.
These forward-looking statements are predictions, not guarantees. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, levels of activity, performance or achievements to materially differ from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those projected, include, but are not limited to, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as guarantees of future events.
The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
CAUTIONARY STATEMENT OF BRUKER CORPORATION
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2009, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
RI Research Instruments GmbH
Dr. Michael Peiniger, +49 2204 843676
RI Research Instruments GmbH
Hanspeter Vogel, +49 2204 843513
Record changed: 2016-03-20
More documents for Bruker Corporation (Group)
-  University of Warwick. (2/17/17). "Press Release: Molecular Phenomenon Discovered by Advanced NMR Facility"....
-  Albany Molecular Research, Inc.. (2/7/17). "Press Release: AMRI Announces Strategic Alliance to Advance Mass Spectrometry Capabilities for Drug Discovery". Albany, NY....
-  Analytik Jena AG. (2/6/17). "Press Release: One Million Tests a Week – Analytik Jena Optimizes the Process for Ultra High Throughput Screening". Jena & Washington, DC....
-  Bruker Corporation. (1/24/17). "Press Release: Bruker Announces Unique and Comprehensive Workflows for Biopharmaceutical Characterization, Automated by Biopharma Compass 2.0". Washington....
-  Bruker Corporation. (1/4/17). "Press Release: Bruker Announces Acquisition of SCiLS GmbH to Advance MALDI Imaging Software Solutions for Life Science, Pharma and Pathology Research Applications". Bremen....
-  Bruker Corporation. (1/4/17). "Press Release: Bruker Announces Acquisition of CMO InVivo Biotech to Expand Molecular Biology, Microbiology and Pathology Consumables and Assay Business". Berlin....
-  Bruker Corporation. (12/21/16). "Press Release: Bruker Delivering 300 Hand-held Chemical Detectors to German BBK". Leipzig....
-  Bruker Corporation. (12/16/16). "Press Release: Bruker Announces Acquisition of Active Spectrum Micro-ESR Business". Billerica, MA....
-  Bruker Corporation. (12/2/16). "Press Release: Bruker Announces Corporate Partnership with International Phenome Centre Network (IPCN) for NMR Technologies and SOPs". Billerica, MA....
-  Bruker Corporation. (11/28/16). "Press Release: Bruker AXS Introduces a New Member to the D8 ADVANCE Family — the D8 ADVANCE Plus". Boston, MA....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)